Seroatlas · Human Serome Atlas

GRIP2

Glutamate receptor-interacting protein 2

Also known as: GRIP2_HUMAN, KIAA1719

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9C0E4
Gene
GRIP2
Ensembl
ENSG00000144596
Chromosome
3
Canonical length
1043 aa
Protein class
Plasma proteins, Predicted intracellular proteins
Subcellular location
Cytosol
Quaternary structure
Homomultimer

OverviewNCBI Gene

Predicted to enable glutamate receptor binding activity. Predicted to be involved in several processes, including neurotransmitter receptor transport, endosome to postsynaptic membrane; positive regulation of AMPA glutamate receptor clustering; and positive regulation of excitatory postsynaptic potential. Predicted to act upstream of or within Notch signaling pathway; artery smooth muscle contraction; and positive regulation of blood pressure. Predicted to be located in dendritic shaft. Predicted to be active in glutamatergic synapse and postsynaptic density, intracellular component. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

1043 residues, UniProt reviewed canonical sequence.

>Q9C0E4|GRIP2
     1  MLCGLSRETP GEADDGPYSK GGKDAGGADV SLACRRQSIP EEFRGITVVE LIKKEGSTLG
    61  LTISGGTDKD GKPRVSNLRP GGLAARSDLL NIGDYIRSVN GIHLTRLRHD EIITLLKNVG
   121  ERVVLEVEYE LPPPAPENNP RIISKTVDVS LYKEGNSFGF VLRGGAHEDG HKSRPLVLTY
   181  VRPGGPADRE GSLKVGDRLL SVDGIPLHGA SHATALATLR QCSHEALFQV EYDVATPDTV
   241  ANASGPLMVE IVKTPGSALG ISLTTTSLRN KSVITIDRIK PASVVDRSGA LHPGDHILSI
   301  DGTSMEHCSL LEATKLLASI SEKVRLEILP VPQSQRPLRP SEAVKVQRSE QLHRWDPCVP
   361  SCHSPRPGHC RMPTWATPAG QDQSRSLSST PFSSPTLNHA FSCNNPSTLP RGSQPMSPRT
   421  TMGRRRQRRR EHKSSLSLAS STVGPGGQIV HTETTEVVLC GDPLSGFGLQ LQGGIFATET
   481  LSSPPLVCFI EPDSPAERCG LLQVGDRVLS INGIATEDGT MEEANQLLRD AALAHKVVLE
   541  VEFDVAESVI PSSGTFHVKL PKKRSVELGI TISSASRKRG EPLIISDIKK GSVAHRTGTL
   601  EPGDKLLAID NIRLDNCPME DAVQILRQCE DLVKLKIRKD EDNSDELETT GAVSYTVELK
   661  RYGGPLGITI SGTEEPFDPI VISGLTKRGL AERTGAIHVG DRILAINNVS LKGRPLSEAI
   721  HLLQVAGETV TLKIKKQLDR PLLPRKSGSL SETSDADEDP ADALKGGLPA ARFSPAVPSV
   781  DSAVESWDSS ATEGGFGGPG SYTPQAAARG TTPQERRPGW LRGSPPPTEP RRTSYTPTPA
   841  DESFPEEEEE DDWEPPTSPA PGPAREEGFW RMFGEALEDL ESCGQSELLR ELEASIMTGT
   901  VQRVALEGRP GHRPWQRGRE VRASPAEMEE LLLPTPLEMH KVTLHKDPMR HDFGFSVSDG
   961  LLEKGVYVHT VRPDGPAHRG GLQPFDRVLQ VNHVRTRDFD CCLAVPLLAE AGDVLELIIS
  1021  RKPHTAHSSR APRSPGPSSP RML

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GRIP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.45
Highest tissue expression
34 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 34 nTPM
  • heart muscle: 12 nTPM
  • tongue: 12 nTPM
  • stomach: 3.9 nTPM
  • placenta: 3.7 nTPM
  • cerebral cortex: 3.1 nTPM

Single-cell type

  • myonuclei: 231 nCPM
  • cardiomyocytes: 105 nCPM
  • vascular smooth muscle cells: 88 nCPM
  • brain inhibitory neurons: 79 nCPM
  • renal collecting duct intercalated cells: 61 nCPM
  • retinal amacrine cells: 59 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • thalamus: 28 nTPM
  • cerebral cortex: 21 nTPM
  • midbrain: 20 nTPM
  • hypothalamus: 14 nTPM
  • amygdala: 14 nTPM
  • basal ganglia: 13 nTPM

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of GRIP2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GRIP2 as an antibody target. Whether an autoantibody or antibody against GRIP2 could matter depends on whether native GRIP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GRIP2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GRIP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/GRIP2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...